Section Arrow
Quote
ALNY.NASDAQ
- Alnylam Pharmaceuticals
Quotes are at least 15-min delayed:2026/11/07 19:17 EST
Regular Hours
Last
 155.94
-0.72 (-0.46%)
Day High 
159.45 
Prev. Close
156.66 
1-M High
238.96 
Volume 
2.83M 
Bid
155.5
Ask
158.8
Day Low
154.3 
Open
155.22 
1-M Low
156.0001 
Market Cap 
20.98B 
Currency 美元 
P/E 8.14 
%Yield -- 
10-SMA 188.55 
20-SMA 208.79 
50-SMA 230.18 
52-W High 479.79 
52-W Low 156.0001 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
19.24/14.30
Enterprise Value
22.22B
Balance Sheet
Book Value Per Share
26.91
Cash Flow
Cash Flow Yield
0.04
Income Statement
Total Revenue
1.83B
Operating Revenue Per Share
12.87
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
KPTIKaryopharm Therapeutics Inc.0.0549-0.0052-8.65%-- 
INOInovio Pharmaceuticals1.215-0.235-16.21%-- 
LABTLakewood-Amedex Biotherapeutics Inc0.3863-0.1543-28.54%-- 
CDTCdt Equity Inc1.31+0.464+54.85%0PE
MRNAModerna254.19+12.73+5.27%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercialRNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.